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Background: There are few studies detailing the incidence, patient outcomes and prognostic factors for
chondrosarcomas (CS). Those that do exist have small sample sizes and/or use older datasets. The pur-
pose of this study was to determine the incidence, overall survival (OS) and prognostic factors for OS of
CS patients, as well as investigate the efficacy of curettage.
Methods: We analyzed data of 2186 patients diagnosed with chondrosarcomas between ’89-‘13 from the
Netherlands Cancer Registry. The effect of risk factors on OS was assessed with a multivariate Cox
regression. Median Follow-up was determined with reversed Kaplan-Meier. OS was estimated using
Kaplan-Meier method.
Results: The relative incidence of CS was 2.88 per million citizens between ’89-’96, 4.15 between ’96-‘04
and 8.78 between ’05-’13. Most of the increase in incidence came from atypical cartilaginous tumours/
grade I chondrosarcoma (ACT/CS I). The 3-, 5- and 10-years survival were, respectively, 96%, 93% and 88%
for ACT/CS I, 82%, 74% and 62% for grade II CS and 38%, 31% and 26% for grade III CS. Prognostics factors
significantly associated with OS were age, histological grade, year of diagnosis, tumour location and size.
Conclusion: The incidence of CS, and especially ACT/CS I, has increased over time, which could be driven
by both an ageing population and increased diagnostic imaging. With the increased number of diagnosed
ACT/CS I, the number of preventative curettages of this tumour has also increased. Despite the supposed
preventative character of this treatment, the incidence of high-grade CS did not decrease.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Chondrosarcomas (CS) are a heterogeneous group of malignant
bone neoplasms with hyaline cartilage differentiation. They are
characterized by the production of cartilage matrix. CS central,
primary, and secondary are the largest subgroup of cartilage tu-
mours and account for approximately 20% of malignant bone tu-
mours, making CS the second most common bone tumour in adults
[1]. Eighty-five percent of the conventional CS arise from the
medullar cavity where they are referred to as primary central CS.
Secondary CS are malignant transformed enchondromas or osteo-
chondromas [2].
Based upon their histopathology, CS are divided into three
grades, where grade I is considered to be low-grade (locally
aggressive) and grade II and III high-grade (malignant). The fourth
group of CS, which could be seen as grade IV; is called dediffer-
entiated chondrosarcoma and makes up 10% of all CS [1]. In 2002
low-grade CS were ‘downgraded’ from malignant to locally
aggressive lesions and renamed atypical cartilaginous tumour
(ACT) [1]. Two other less common types of CS are mesenchymal and
clear cell CS. Both of these have very different characteristics,
treatment and prognosis than other CS subtypes. Mesenchymal is a
highly malignant tumour with strong tendency towards local
recurrence. On the contrary, clear cell is a low-grade variant that
can usually be cured with en bloc excision [1,3].
For ACT/CS I, which is locally aggressive, curettage (with either
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cryosurgery or phenolisation) is the standard treatment in the ex-
tremities. The effectiveness of curettage in preventing trans-
formation into high-grade CS has, however, not been proven. CS of
the axial skeleton and grade II and grade III CS in the extremities are
generally resected with free margins (Appendix A). Surgical treat-
ment is considered the only curative treatment modality as CS is
less sensitive to both radiotherapy and chemotherapy [4]. Radio-
therapy can be of use in two situations: after incomplete resection
for local control with curative intent or if resection is not an option.
In the latter case the intention is to palliate [5,6].
Consensus exists that age, grade and localization are of prog-
nostic value for survival [7e9]. Additionally, larger tumours and
fractures are associated with worse outcome [3,8]. Gender is not
associated with survival [8]. Local recurrence and distant metas-
tasis are associated with a worse outcome in univariate analysis
[9e11]. Studies investigating prognostic factors often have small
sample sizes and use more covariates in their multivariate Cox
regression models than is recommended in statistical literature or
neglect to include known important prognostic factors (based on
clinical experience and literature). Studies that do not suffer from
these shortcomings are scarce, and those that exist are several
decades old and therefore in need of confirmation in a modern
setting.
Themain objective of this study was to determine the incidence,
overall survival (OS) and prognostic factors associated with OS for
CS in the Netherlands over the last 25 years. Secondary objective
was to evaluate the effect of curettage of ACT/CS I in preventing
transformation into high-grade CS. We hypothesized that the
increased number of ACT/CS I treated with preventative curettage
has not led to a decrease in the incidence of high-grade CS.
2. Methods
Studydesign. This is a retrospective observational study.We used
data from the Netherlands Cancer Registry (NCR-IKNL), a retrospec-
tive national registry that records all cases of cancer in the
Netherlands, covering a population of approximately 16.9 million.
Patients were seen at a tertiary dedicated bone tumour centre, that
hasamultidisciplinary teamofdedicatedbonetumourpathologist(s),
radiologists, and orthopaedic surgeons. We evaluated 2186 consec-
utive patients with a histologically proven chondrosarcoma treated
between ’80-‘13, resulting in1615eligiblepatients afterexcluding571
patients for one or more of the following reasons: missing data for
relevant covariates, treatment without curative intent, CS subtypes
periosteal, dedifferentiated, mesenchymal, clear cell or a multifocal
tumour (Fig. 1, flow diagram detailing the inclusion process).
Variables. Starting point was the date of diagnosis. The radio-
logical diagnosis and -grade was combined with histological tissue
diagnosis, according to the WHO classification of bone tumours.
Data on diagnosis, grading, treatment and outcome is collected by
trained registry personnel of this independent organization
through a national pathology database, supplemented by data from
medical records. Tumour sizewas defined asmaximum diameter at
pathologic analysis. Tumour grade was classified as (ACT/)CS
I< grade II< grade III. Tumour locationwas based on ICD-0-3 codes.
Survival data are available through a link with municipal popula-
tion registries [13]. If patients were lost to follow-up, the last
documented endpoint was used.
Participants. Table 1 summarizes characteristics for all patients
with a chondrosarcoma. Themedian follow-upwas 7.4 years (range
5 dayse26.1 years). Mean age at time of diagnosis was 50.6± 16.2
years. Slightly more women (53%) than men (47%) were affected.
The majority of CS were conventional (95.2%), for more details on
the other subtypes please refer to Appendix B. ACT/CS I was the
most common grade with 1437 (65.7%) patients, versus 404 (18.5%)
for grade II and 150 (6.9%) for grade III. Tumour size was 8 cm or
Fig. 1. Flowchart representing the selection process for patients that were incorpo-
rated into the analysis.
Abbreviations: N, number of patients; ICD-O-3: International Classification of Diseases for
Oncology, 3rd ed. [12]; ACT/CS I, atypical cartilaginous tumor/chondrosarcoma grade I.
Table 1
Demographic and clinical characteristics of the study cohort.
Characteristica Total,
n¼ 2186
Period of diagnosis, n (%)
‘89-’96 351 (16.1)
’97-’04 530 (24.2)
’05-’13 1305 (59.7)
Age: Mean± SD, y 50.6± 16.2
‘89-’96 51.3± 19.0
’97-’04 50.7± 17.4
’05-’13 50.3± 14.9
Gender, n (%)
Male 1033 (47.3)
Female 1153 (52.7)
Histological, n (%)
Conventional 2082 (95.2)
Periosteal 36 (1.6)
Mesenchymal 11 (0.5)
Clear cell 13 (0.6)
Dedifferentiated 44 (2.0)
Grade, n (%)
ACT/CS I 1437 (65.7)
II 404 (18.5)
III 150 (6.9)
Unknown 195 (8.9)
Size in cm, n (%)
8 cm 1488 (68.6)
>8 cm 445 (20.5)
Multifocal 30 (1.4)
Unknown 205 (9.3)
Site, n (%)
Extremities 1592 (72.8)
- Upper (excl. hand and wrist) 412 (18.8)
- Hand/Wrist 149 (6.8)
- Lower (excl. knee/ankle/foot) 987 (45.2)
- Knee/Ankle/Foot 44 (2.0)
Axial skeleton 387 (17.7)
- Rib/Sternum/Clavicle 242 (11.1)
- Skull (excl. mandible) 93 (4.3)
- Mandible 5 (0.2)
- Spine 47 (2.2)
Pelvic bones/sarcum/coccyx 207 (9.5)
a Full cohort. Abbreviations: N, number of patients; SD, standard deviation;
ACT/CS I, atypical cartilaginous tumor/chondrosarcoma grade I.
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smaller in 68.6% of the cases. Tumour locations were in descending
order: lower extremity (45.2%), upper extremity (18.8%), rib, ster-
num or clavicle (11.1%), pelvis, sacrum or coccyx (9.5%) hand or
wrist (6.8%), skull (4.3%), spine (2.2%), knee, ankle or foot (2.0%),
mandible (0.2%).
Statistical analysis. OS was estimated using Kaplan-Meier. The
effect of possible prognostic factors on OS were estimated with a
multivariate Cox regression model. We stratified for histological
grade in this model, as grade violated the proportional-hazards-
assumption. To determine if the increase in incidence might be
attributed to an ageing population, incidences were calculated per
number of citizens in all age groups per time period. For this, data
from the governmental institution ‘Statistics Netherlands’ was used
[14]. Median follow-up time was estimated with reversed Kaplan-
Meier method.
3. Results
Incidence. When adjusting the absolute number of CS per year
for number of citizens per year, the incidence of chondrosarcoma
was 2.88 per million citizens between ’89-’96, 4.15 between ’96-‘04
and 8.78 between ’05-’13. Most of the increase in incidence came
from ACT/CS I, with incidence increasing from 1.20 per million in
’89-’96 to 6.63 in ’05-’13. Average incidence for high-grade (grade II
Fig. 2. Incidence of CS between 1989 and 2013 by grade.
Blue, grade I; red, grade II and green, grade III.
b) Incidence of low-grade chondrosarcoma in comparison with number of MRI examinations over time.
Black, incidence of CS grade I and red, number diagnostic images per year [15]. The amount of diagnostic images in 1999 and 2000 are unknown. The data collection started in 1993.
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and grade III) tumours was 0.95 per million in ’89-’96 and 1.81 in
’05-’13 (Fig. 2a). The number of diagnostic images in the
Netherlands also increased over time (Table 2). The relation be-
tween incidence rates of ACT/CS and the number of diagnostic
images in the Netherlands are presented in Fig. 2b. For a more
detailed overview of incidence rates per grade per year, we refer to
appendix C.
Survival and prognostic factors. The 3-, 5- and 10-years overall
survival for ACT/CS I were, respectively, 96% (95%CI: 94e98%), 93%
(95%CI: 91e95%) and 88% (95%CI: 86e90%). For grade II CS this was
82% (95%CI: 78e86%), 74% (95%CI: 70e78%) and 62% (95%CI:
56e68%), respectively. Lastly for grade III CS this was 38% (95%CI:
30e46%), 31% (95%CI: 23e39%) and 26% (95%CI: 18e34%) (Fig. 3).
A multivariate Cox regression model, based on clinically rele-
vant variables, was used to assess the effect of prognostic factors on
OS. Only a small number of patients received (neo)adjuvant
radiotherapy and/or chemotherapy. Therefore (neo)adjuvant
therapies were not included in the analysis. At the end of follow-up,
a total of 252 patients had died. Variables are categorical, except for
agewhich is linear. The hazard ratio is per 10 years with a reference
of 50 years (mean age at diagnosis). This means that the HR of age of
1.78 represents the increase in risk of a 60-years-old compared to a
50-years-old. Prognostic factors that had a significant negative as-
sociationwith OS were increasing age (HR¼ 1.78; 95%CI:1.63e1.95;
p< .001) earlier period of diagnosis (for ’97-’04: HR¼ 1.68; 95%
CI:1.20e2.35; p¼ .003; for ’89-’96: HR¼ 2.23; 95%CI:1.57e3.15;
p< .001) and tumour size >8 cm (HR¼ 1.48; 95%CI:1.1.-1.97;
p¼ .007). Location in the pelvis, sacrum or coccyx (HR¼ 1.76; 95%
CI:1.24e2.50; p¼ .002) and spine (HR¼ 1.23; 95%CI:0.91¼1.67;
p¼ .173) had a worse outcome than location in the extremities
(Table 3).
Patients diagnosed with extremely rare chondrosarcoma sub-
types (periosteal (juxta-cortical), mesenchymal, clear cell and
dedifferentiated) are described in Appendix B.
4. Discussion
To our knowledge, this is the only recent study that incorporated
both the effect modifiers age and grade in their analysis with
(overall) survival as an endpoint. Only one study used a statistic
model to determine prognostic factors for different locations [11].
In that study, 194 patients were included in a multivariate Cox
analysis, with 94 deaths and 11 covariates. This should be regarded
as a relatively marginal sample size, justifiable by the rareness of
the disease. Inclusion ended after ’93, while in our study the 89% of
the patients were included later that ’93, meaning that the majority
of our patients were treated according to more recent guidelines.
Others that used statistical models unfortunately did not perform
multivariate analysis [8]. Additionally, other important papers on
the topic need confirmation in a modern setting, as patients in one
studywere included between ’11-’90 and in another study between
’48-’74 [3,10].
Incidence. We observed a marked increase in overall incidence
over time during the period covered. This finding is in line with
data from the UK [16]. The observed increase could be due to an
increase in the true incidence, as the Netherlands is an ageing so-
ciety and development of CS is age dependent [1,17]. Furthermore,
it could reflect an increase in incidental findings due to an increase
Table 2
Incidence rates per time period.
Period of diagnosis Grade N Incidence (/million/year)
89-'96 ACT/CS I 146 1.20
II 83 0.68
III 33 0.27
Unknown 89 0.73
Total
High-grade (II&III)
351
116
2.88
0.95
97-'04 ACT/CS I 306 2.40
II 116 0.91
III 53 0.41
Unknown 55 0.43
Total
High-grade (II&III)
530
169
4.15
1.32
05-'13 ACT/CS I 985 6.63
II 205 1.38
III 64 0.43
Unknown 51 0.34
Total
High-grade (II&III)
1305
269
8.78
1.81
Incidence per million citizens.
AbbreviationsN, number of patients; ACT/CS I, atypical cartilaginous tumor/chon-
drosarcoma grade I.
Fig. 3. Overall survival for chondrosarcoma.
Green, atypical cartilaginous tumors/grade I chondrosarcoma; blue, grade II; red,
grade III. Log-rank test of the association of grade and overall survival (p< .001).
Table 3
Cox multivariate analysis of the effect of patient- and tumor characteristics on
overall survival stratified for tumor grade (n¼ 1615).
HR 0.95% CI P-value
Sex
Male Ref e e
Female 0.94 0.73e1.23 .671
Age, y*
50 Ref e e
1.78 1.63e1.95 <.001
Period of diagnosis
’05-‘13 Ref e e
’97-’04 1.68 1.20e2.35 .003
’89-‘96 2.23 1.57e3.15 <.001
Location
Extremities Ref e e
Spine 1.23 0.91e1.67 .173
Pelvis/sacrum/coccyx 1.76 1.24e2.50 .002
Tumor size
8 cm. Ref e e
>8 cm. 1.48 1.11e1.97 .007
All patients have received surgical treatment for their chondrosarcoma. A p-value of
<.05 is considered statistically significant.*Age is in steps of 10 years with a refer-
ence of 50 years.Abbreviations: CI, confidence interval; HR, hazard ratio; Ref,
reference category.
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in diagnostic imaging [18]. For example, the number of MRI scans
increased tenfold between ’99-‘14 in the Netherlands (Fig. 2b).
Previous studies how shown that the majority of ACT/CS I were
incidental findings [19,20]. On the contrary, incidental findings are
uncommon for high-grade CS, because they destruct the cortex and
have faster infiltrative growth patterns with corresponding symp-
toms [21e24].
The share of CS consisting of ACT/CS I increased from 42% ‘89-‘96
to 75% ‘05-’13. Although it has been reported in literature that low-
grade CS can transform into higher grades, true observational
studies reporting the risk of progression are lacking. Increased
diagnostic imaging could therefore have the effect of showing a
one-off increase in ACT/CS I0 share of the total, given some grade II
and III tumours would be detected in their earlier stage, before
possible transformation.
The use of curettage to treat ACT/CS I has increased over time as
detection rates have gone up. If the treatment is effective in pre-
venting transformation into high-grade CS, we would expect to see
a decreased incidence of grade II and III over time. In fact, incidence
of grade II and III has increased from 0.95 (89-96) to 1.81 (05-13)
per million. Part of this can be explained by the ageing of society;
applying 89-96 incidence per age group to 05-13 demographics
would see incidence rise to 1.1. Therefore, ageing population is not
the only cause for the incidence rise to 1.81. The remainder of the
increase could be explained by increased diagnostic imaging.
Our incidence numbers exceed the few that are available in
existing literature. A study using national cancer registration data
in the UK between ‘79-‘03 found an incidence of 1.56 per million
between ’79-‘03, while a study on the population of East Denmark
found an incidence of 1.46 between ’83-‘96 [17,25]. We believe that
divergent outcomesmay be explained by the historical data used by
previously mentioned studies, and by progressive difference in
grading approaches, including grading of borderline lesions as
malignant grade I CS, which account for the majority of CS.
Survival and prognostic factors. The 5-years overall survival in
our study was 93% (95%CI: 91e95%) for ACT/CS I, 74% (95%CI:
70e78%) for grade II and 31% (95%CI: 23e39%) for grade III. These
survival percentages at 5 years after diagnosis are broadly in line
with existing literature, which shows for grade I 89%, 90% and 96%,
for grade II 62%, 63%, 81% and for grade III of 39%, 43% and 53%
(Appendix D) [3,8,10,11]. When interpreting results on survival, one
must take into account that of the patients with ACT/CS I, more
received surgical treatment recently in comparison to grade II and
III. Therefore, a time-effect might overestimate the better survival
results for ACT/CS I in comparison to grade II and III.
Also in line with literature, age, tumour grade, -size and
-localization are prognostic factors for OS [3,7e9,26]. Additionally,
being diagnosed ’05-’13 rather than in earlier periods, ’89-’96 and
’97-’04, was associated with better OS (Table 3). This could be due
to better treatment; however, it could also reflect lead time bias,
due to increased diagnostic imaging, and/or changes in CS grading.
In this study we did not evaluate the association between radio-
and chemotherapy and OS for primary resectable CS. However,
findings of a small study in patients with unresectable CS and a
study in rats suggest chemotherapy might be beneficial [5,27]. No
randomized controlled trials have been undertaken to support this.
Furthermore, some studies suggest that OS improves when
applying adjuvant radiotherapy to patients with high-risk CS with
non-wide surgical margins [6].
The true incidence of enchondromasmight be close to 2.8%e2.9%
according to two studies reviewing routine knee MR images for
enchondromas [19,20], and the incidence of high-grade CS at that
same time period in our results is 0.0001%. Thus, if this actually
happens, it is expected that the amount ofmalignant transformation
is small. Therefore, even if preventative curettage does have some
effectonpreventingmalignant transformation,weare confident that
this percentage is presumably small. As we are not able to explicitly
split the potential effect of lower transformation rates from the
counter effect of increased diagnostic imaging, we cannot draw any
definitive conclusions on the efficacy of curettage. However, we do
not find any proof that it achieved its desired outcome in our study.
5. Conclusions
The 3-, 5- and 10-years survival were respectively, 96%, 93% and
88% for ACT/CS I, 82%, 74% and 62% for grade II CS and 38%, 31% and
26% for grade III. Prognostic factors for survival were in line with
existing literature. The incidence of CS, and especially ACT/CS I, has
increased over time. This could be driven by an ageing population
and/or the increased amount of diagnostic imaging. The question
whether the negative side-effects of treating the rapidly growing
group of diagnosed ACT/CS I with curettage outweigh the potential
benefits, is therefore an important one, and requires more research.
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Appendix B
In total 36 (1,7%) patients were diagnosed with periosteal
chondrosarcoma (CS), of which all received surgery for their CS
without adjuvant therapy. After an average follow-up (FU)
duration of 11.5 years, 4 (11%) had died. Mesenchymal CS was the
most rare type with only 11 patients diagnosed over 25 years (0,5%
of the whole population diagnosed with CS). Ten patients had
received surgical treatment, of which 3 with adjuvant radio-
therapy (RT) and 2 with both RT and chemotherapy (CT). After an
average FU of 7.9 years, 8 (73%) had died. In the group with clear
cell CS only 3 patients (23%) that had died at time of FU, 5.2 years.
Only one patient did not receive any treatment, the other 12
received solely surgical treatment. The second largest subtype
consisted of patients diagnosed with dedifferentiated CS, with a
total of 44 patients (2.0%). Probably imputable to the infaust
prognosis only 27 (61%) received surgery for their CS. After an
average follow-up (FU) duration of 1.8 years, 38 (86%) of the pa-
tients with dedifferentiated CS had died. The six surviving were all
surgically treated, two with adjuvant RT.
Appendix C
A simplified overview of conventional treatments for different histological grades of
CS.
Grade
Benign lesions Watchful waiting
ACT/CS I Watchful waiting/Curettage [28e30] Resection in axial skeleton
Grade II* Resection [6]
Grade III* Resection [6]
*Possible adjuvant radiotherapy in intralesional resections [6].
Abbreviation: ACT/CS I, atypical cartilaginous tumor/chondrosarcoma grade I.
Chondrosarcomas (n) N (%) Age at diagnosis (average) Surgical treatment No surgical treatment
No RT RT Total No RT RT Total
No CT CT No CT CT No CT CT No CT CT
9220 NNO 2082 (95,2%) 50 years 1842 8 61 2 1913 127 7 31 3 168
9221 Periosteal 36 (1,7%) 38 years 36 0 0 0 36 0 0 0 0 0
9240 Mesenchymal 11 (0,5%) 38 years 3 2 3 2 10 0 1 0 0 1
9242 Clear cell 13 (0,6%) 43 years 12 0 0 0 12 1 0 0 0 1
9243 Dedifferentiated 44 (2,0%) 61 years 19 2 6 0 27 13 1 2 1 17
Grand Total 1982 (100%) 50 years 1912 12 70 4 1861 141 9 33 4 187
Incidence of chondrosarcomas for both histological grade and population size.
Year Population size Overall ACT/CS I Grade II Grade III Unknown
Incidence N Incidence N Incidence N Incidence N Incidence N
1989 14849000 3.7 55 1.8 27 0.7 10 0.2 3 1.0 15
1990 14951000 2.3 35 0.7 11 0.8 12 0.1 1 0.7 11
1991 15070000 2.5 37 0.7 10 0.7 11 0.3 5 0.7 11
1992 15184000 2.5 38 0.9 13 0.7 11 0.3 5 0.6 9
1993 15290000 2.8 43 1.0 15 0.9 14 0.4 6 0.5 8
1994 15383000 3.4 53 2.0 30 0.5 8 0.1 2 0.8 13
1995 15459000 2.5 39 0.7 11 0.6 10 0.4 6 0.8 12
1996 15528000 3.3 51 1.9 29 0.5 7 0.3 5 0.6 10
1997 15611000 4.4 69 2.0 32 1.3 20 0.4 6 0.7 11
1998 15706000 3.4 54 1.8 29 1.0 15 0.3 5 0.3 5
1999 15812000 3.7 58 2.1 33 0.9 14 0.3 4 0.4 7
2000 15924000 3.5 56 2.2 35 0.5 8 0.4 6 0.4 7
2001 16044000 4.4 70 2.0 32 1.4 22 0.6 9 0.4 7
2002 16149000 4.5 73 3.2 52 0.5 8 0.4 6 0.4 7
2003 16225000 3.8 61 2.0 33 0.8 13 0.6 9 0.4 6
2004 16282000 5.5 89 3.7 60 1.0 16 0.5 8 0.3 5
2005 16320000 4.9 80 3.6 58 1.0 17 0.1 1 0.2 4
2006 16346000 7.4 121 5.4 88 1.4 23 0.2 3 0.4 7
2007 16358000 7.8 127 5.7 94 1.4 23 0.3 5 0.3 5
2008 16405000 6.3 103 4.6 76 1.1 18 0.4 6 0.2 3
2009 16485000 10.3 170 7.2 118 2.0 33 0.7 12 0.4 7
2010 16575000 10.1 168 7.5 125 1.4 24 0.8 13 0.4 6
2011 16656000 11.6 193 9.7 162 1.2 20 0.5 8 0.2 3
2012 16730000 11.8 197 9.7 162 1.4 24 0.4 7 0.2 4
2013 16780000 8.7 146 6.1 102 1.4 23 0.5 9 0.7 12
Average 5.4 3.5 1.0 0.4 0.5
Total 2186 1437 404 150 195
Incidence per million citizens.
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Overall survival reported in literature
Study Number of patients* Grade Overall survival (%)
5-years 10-years
Andreou et al., 2011 [8] N¼ 115
(68 extremities, 47 axial/pelvis)
I
II
III
Dedifferentiated
All
89
63
39
-
72
89
58
33
-
69
Bj€ornsson et al., 1998 [10] N¼ 344
(208 long bones,
109 pelvis,
27 scapula)
I
II & III
Dedifferentiated
All
89
57
e
77
e
e
e
e
Evans et al.
1977 [3]
N¼ 81
(20 axial,
20 long bones,
23 pelvis, 5 scapula)
I
II
III
Dedifferentiated
All
90
81
43
e
e
83
64
29
e
e
Fiorenza et al., 2002 [11] N¼ 153
(101 long bones
52 pelvis)
I
II
III
Dedifferentiated
All
96
62
53
e
78
89
53
38
e
70
*All patients were diagnosed with both primary chondrosarcomas and treated at tertiary centers.
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